• Ribociclib Succinate: Evidence and Scope

  2026-10-14

  APExBIO identifies Ribociclib succinate, or LEE011 succinate, as a selective CDK4/6 inhibitor for cancer research. The product description supports a documented target and physicochemical profile, but it does not provide an identity-matched study, quantitative potency data, comparative outcomes, or independent validation of the proposed mechanism.

• Chloroquine, Autophagy, and HBV: Evidence Boundaries

  2026-10-14

  A source-grounded overview of how a 2025 study links HBsAg, TBK1 signaling, interferon suppression, and incomplete autophagy, while distinguishing those findings from supplier-level claims about Chloroquine diphosphate in cancer research.

• Ellagic Acid, CK2, and Senolytic Evidence

  2026-10-13

  Ellagic acid is described by the supplied APExBIO product record as a selective ATP-competitive casein kinase 2 inhibitor, but the cited machine-learning senolytic study does not establish ellagic acid as a senolytic. The evidence supports a distinction between biochemical CK2 activity and the much narrower question of selective senescent-cell elimination.

• What Senolytic Fibroblast Findings Actually Show

  2026-10-13

  A source-grounded overview of a 2018 fibroblast study reporting context-dependent senolytic activity for azithromycin and roxithromycin, with emphasis on assay interpretation, provenance, and limits of generalization.

• What the SARS-CoV-2 RNAi Screen Shows

  2026-10-12

  Kerr et al. identify vesicle-mediated exocytic transport, including Rab11a-associated cargo delivery, as a host process supporting SARS-CoV-2 release. The study used CDKI-73 as a CDK9-directed pharmacological probe; its findings should not be treated as evidence that the distinct compound SNS-032, also known as BMS-387032, has equivalent antiviral activity.

• Azithromycin, Roxithromycin and Senolytic Evidence

  2026-10-12

  Ozsvari et al. reported selective effects of azithromycin and roxithromycin against DNA-damage-induced senescent human fibroblasts in vitro. The findings support further investigation of macrolide-associated senolytic activity, but they do not establish clinical anti-aging efficacy or demonstrate that a single senescence biomarker is sufficient for senescent cell detection.

• Bufalin Targets STK33 in Triple-Negative Breast Cancer

  2026-10-10

  A 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct binding target and degradation-sensitive protein for Bufalin in triple-negative breast cancer models. Its multi-layered evidence connects STK33 binding to CCAR1 stabilization, tumor-cell growth, and responses in cell, animal, and patient-derived organoid systems, while remaining preclinical rather than clinical evidence.

• MAPK10, KRT16, and NSCLC Metastasis

  2026-10-09

  A 2026 International Journal of Biological Macromolecules study identifies a MAPK10–KRT16–RNF213 pathway that links phosphorylation to ubiquitin-dependent degradation and suppression of non-small cell lung cancer metastasis. The findings provide a mechanistic framework for interpreting MAPK10 as a prognostic marker, while the small clinical sample and model-specific evidence limit immediate therapeutic extrapolation.

• Reversine: Product Identity and Evidence Limits

  2026-10-09

  Reversine is an APExBIO research product described as an Aurora kinase inhibitor for conceptual studies of mitotic regulation and cancer biology; no matched paper evidence is available here.

• CDK4/6–BET Synergy in Pancreatic Cancer

  2026-10-08

  Gu et al. report that combining CDK4/6 inhibition with BET inhibition suppresses pancreatic ductal adenocarcinoma growth while counteracting the pro-invasive and EMT-associated effects observed with CDK4/6 inhibition alone. The study connects this response to GSK3β-mediated Wnt/β-catenin activity and crosstalk with TGF-β/Smad signaling, providing a mechanistic rationale for combination-focused PDAC research.

• DGLA–ACSL4 Ferroptosis in AML: Study Insights

  2026-10-08

  A 2025 Translational Oncology study identifies dihomo-γ-linolenic acid (DGLA) as a ferroptosis-inducing lipid in acute myeloid leukemia and places ACSL4 at the center of this response. The findings connect fatty-acid remodeling with leukemia-cell vulnerability, while remaining preclinical and requiring validation in patient-derived systems.

• Saracatinib and the Reelin–SFK Translational Bridge

  2026-10-07

  Saracatinib (AZD0530) offers a useful chemical lens for studying Src family kinase biology across cancer and neuroscience. This thought-leadership analysis connects vendor-reported oncology findings with a PNAS study showing that Reelin–Apoer2–SFK signaling permits ketamine-associated synaptic plasticity in mice, while defining the evidence boundaries that translational researchers should preserve.

• Moxifloxacin: From Gyrase to Cell Phenotype

  2026-10-07

  Moxifloxacin research is strongest when target-level evidence is separated from cellular and systemic phenotypes. This article applies a provenance-first framework to fluoroquinolone antibiotic mechanism, retinal-cell toxicity, and metabolic findings without overstating what each model can prove.

• Primidone: From Biomarker to Mechanism

  2026-10-06

  Primidone, also known as Mysoline, offers a valuable case study in how drug repurposing can connect RIPK1 biology, ALS biomarkers, and TRPM3-related disease research. This evidence-focused analysis separates reported mechanisms from translational claims and defines where the data remain preliminary.

• BI-1347 and CDK8/19: Translational Signals

  2026-10-06

  A source-grounded analysis of how CDK8/19 biology may inform translational research around BI-1347, while separating vendor-reported potency from validated target, cellular, and disease evidence.

8042 records 1/537 page Next 12345 下5页 Last page